{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T05:58:17Z","timestamp":1790315897910,"version":"4.1.0"},"reference-count":26,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:00:00Z","timestamp":1759363200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.mdpi.com"],"crossmark-restriction":true},"short-container-title":["Biomedicines"],"abstract":"<jats:p>Background\/Objectives: The diagnosis of Mycobacterium tuberculosis complex (MTBC) and nontuberculous mycobacterial (NTM) infections is accomplished by three main diagnostics methods: smear microscopy, culture, and molecular testing. Diagnostic algorithms used by laboratories can significantly impact clinical and infection control management. Current Canadian Tuberculosis Standards recommend the use of nucleic acid amplification testing (NAAT) for smear-positive patients and smear-negative patients upon request. An alternative algorithm is to utilize NAAT in the Panel approach on all samples, pulmonary and extrapulmonary, to potentially reduce time to diagnosis and treatment. This alternative approach was implemented in November 2019 at the Newfoundland and Labrador Public Health and Microbiology Laboratory (NL PHML) using a laboratory-developed multiplex real-time PCR (LDT m-qPCR) assay targeting Mycobacterium spp. (Myco spp.) and MTBC, performed in parallel with smear and culture. Methods: To investigate the impact of this alternate testing approach, we conducted an observational retrospective analysis of laboratory diagnostic and treatment data, recognizing that temporal changes in epidemiology, clinical practice, and laboratory workflow may also have influenced outcomes. To complete this, study data from three years before and four years after implementation were gathered. Results: The sensitivity\/specificity of the smear, m-LDT qPCR-MTBC, m-LDT qPCR-Myco spp., and culture assays in this study were 18.1%\/100%, 96.7%\/99.8%, 47.6%\/99.0%, and 96.8%\/100%, respectively. The gold standard utilized for these calculations was clinical diagnosis for active MTBC disease and culture for NTM infections, recognizing that the use of clinical diagnosis may introduce subjectivity. The Panel approach reduced the time to diagnosis of tuberculosis MTBC by 29 days (p &lt; 0.0001) for NL PHML, and when modelled for a laboratory with rapid culture identification, diagnosis was reduced by 14 days (p = 0.003). Among non-empirically treated tuberculosis patients, the time to treatment was decreased by 25.5 days (p &lt; 0.001). For NTM infections, rapid diagnostics only affected one patient\u2019s treatment. This finding agrees with clinical management guidelines, which do not routinely utilize rapid diagnostics for the diagnosis of disease or treatment decisions. The cost implications of additional NAAT testing were calculated to be an increase of CAD 23.62 per sample. Conclusions: Our findings support the adoption of a molecular assay for MTBC as an initial diagnostic tool to decrease time to diagnosis and time to treatment, depending on local epidemiology and irrespective of smear status. Utilizing a molecular assay for genus level identification of NTM had minimal impact on clinical management suggesting its limited diagnostic utility in a broad population setting.<\/jats:p>","DOI":"10.3390\/biomedicines13102416","type":"journal-article","created":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T15:07:48Z","timestamp":1759417668000},"page":"2416","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Evaluating the Impact of a Molecular Diagnostic Algorithm on Tuberculosis and Nontuberculous Mycobacterial Infections in Newfoundland and Labrador, Canada"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8844-4981","authenticated-orcid":false,"given":"Robert","family":"Needle","sequence":"first","affiliation":[{"name":"Division of Biomedical Sciences, Memorial University of Newfoundland, St. John\u2019s, NL A1B 3V6, Canada"},{"name":"NL Heath Services, Public Health and Microbiology Laboratory, St. John\u2019s, NL A1A 3Z9, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Pathology & Laboratory Medicine, University of Ottawa, Ottawa, ON K1H 8M5, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5526-6741","authenticated-orcid":false,"given":"Hafid","family":"Soualhine","sequence":"additional","affiliation":[{"name":"National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB R3E 3R2, Canada"},{"name":"Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, MB R3E 0T4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Yoshida","sequence":"additional","affiliation":[{"name":"National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB R3E 3R2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Jiao","sequence":"additional","affiliation":[{"name":"NL Heath Services, Public Health and Microbiology Laboratory, St. John\u2019s, NL A1A 3Z9, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0051-746X","authenticated-orcid":false,"given":"Rodney","family":"Russell","sequence":"additional","affiliation":[{"name":"Division of Biomedical Sciences, Memorial University of Newfoundland, St. John\u2019s, NL A1B 3V6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,2]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (2024). Global Tuberculosis Report 2024, WHO."},{"key":"ref_2","first-page":"755","article-title":"The ultimate results in 1654 cases of tuberculosis treated at the Modern Woodmen of America Sanitorium","volume":"2","author":"Rutledge","year":"1919","journal-title":"Am. Rev. Tuberc."},{"key":"ref_3","unstructured":"Public Health Agency of Canada (2025, May 20). Tuberculosis Disease in Canada, 2023 (Infographic), Available online: https:\/\/www.canada.ca\/en\/public-health\/services\/publications\/diseases-conditions\/tuberculosis-disease-2023-infographic.html."},{"key":"ref_4","unstructured":"Public Health Agency of Canada (2025, May 20). Tuberculosis in Canada: Epidemiological Update 2022, Available online: https:\/\/www.canada.ca\/en\/public-health\/services\/publications\/diseases-conditions\/tuberculosis-canada-epidemiological-update-2022.html."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"77","DOI":"10.14745\/ccdr.v43i34a04","article-title":"Tuberculosis in Canada\u2014Summary 2015","volume":"43","author":"Gallant","year":"2017","journal-title":"Can. Commun. Dis. Rep."},{"key":"ref_6","unstructured":"Public Health Agency of Canada (2025, May 20). Tuberculosis Disease in Canada\u20142008-2018 Data, Available online: https:\/\/open.canada.ca\/data\/en\/dataset\/4dbb9bff-022d-4aab-a11d-0a2e1b0afaad\/resource\/1ff8f1b6-02a8-425a-bd0b-af9495d2e53c."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"599-vi","DOI":"10.1016\/S0272-5231(02)00020-5","article-title":"Diagnosis, differentiating colonization, infection, and disease","volume":"23","author":"Catanzaro","year":"2002","journal-title":"Clin. Chest Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1016\/S0140-6736(15)60570-0","article-title":"WHO\u2019s new end TB strategy","volume":"385","author":"Uplekar","year":"2015","journal-title":"Lancet"},{"key":"ref_9","unstructured":"Public Health Agency of Canada (2025, May 20). Government of Canada\u2019s Tuberculosis Response (2025): Working Towards Tuberculosis Elimination, Available online: https:\/\/www.canada.ca\/en\/public-health\/services\/publications\/diseases-conditions\/government-tuberculosis-response-2025-working-towards-tuberculosis-elimination.html."},{"key":"ref_10","first-page":"333","article-title":"Canadian Tuberculosis Standards 8th edition: What\u2019s new? And what\u2019s next?","volume":"6","author":"Menzies","year":"2022","journal-title":"Can. J. Respir. Crit. Care Sleep Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e00860-22","DOI":"10.1128\/spectrum.00860-22","article-title":"Feasibility and sensitivity of saliva GeneXpert MTB\/RIF Ultra for tuberculosis diagnosis in adults in Uganda","volume":"10","author":"Byanyima","year":"2022","journal-title":"Microbiol. Spectr."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Boldi, M.O., Denis-Lessard, J., Neziri, R., Brouillet, R., von-Garnier, C., Chavez, V., Mazza-Stalder, J., Jaton, K., Greub, G., and Opota, O. (2023). Performance of microbiological tests for tuberculosis diagnostic according to the type of respiratory specimen: A 10-year retrospective study. Front. Cell. Infect. Microbiol., 13.","DOI":"10.3389\/fcimb.2023.1131241"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1378\/chest.14-2948","article-title":"The feasibility, accuracy, and impact of Xpert MTB\/RIF testing in a remote Aboriginal community in Canada","volume":"148","author":"Alvarez","year":"2015","journal-title":"Chest"},{"key":"ref_14","unstructured":"Government of Newfoundland and Labrador (2025, July 20). Guideline for Preventing the Transmission of Mycobacterium tuberculosis Across the Continuum of Care, Available online: https:\/\/www.gov.nl.ca\/hcs\/files\/Tuberculosis-v2019.pdf."},{"key":"ref_15","unstructured":"Clinical and Laboratory Standards Institute (2008). Laboratory Detection and Identification of Mycobacteria; Approved Guideline, CLSI. CLSI document M48-A."},{"key":"ref_16","unstructured":"Public Health Agency of Canada (2025, May 25). Biosafety Directive for Mycobacterium tuberculosis Complex (MTBC), Available online: https:\/\/www.canada.ca\/en\/public-health\/services\/laboratory-biosafety-biosecurity\/biosafety-directive-mycobacterium-tuberculosis-complex-mtbc.html."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"96","DOI":"10.5152\/eajm.2014.23","article-title":"Comparison of the mycobacterium growth indicator tube method and the method of proportion for drug susceptibility testing of mycobacterium tuberculosis","volume":"46","author":"Aktas","year":"2014","journal-title":"Eurasian J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1007\/s10096-009-0793-6","article-title":"Real-time PCR strategy and detection of bacterial agents of lymphadenitis","volume":"28","author":"Angelakis","year":"2009","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.bjid.2013.07.011","article-title":"Duplex realtime PCR method for Epstein-Barr virus and human DNA quantification: Its application for post-transplant lymphoproliferative disorders detection","volume":"18","author":"Fellner","year":"2014","journal-title":"Braz. J. Infect. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Malavika, K.R., Ellappan, K., and Joseph, N.M. (2023). Diagnostic performance of two commercial MPT64 assays for the identification of Mycobacterium tuberculosis complex from liquid culture. Indian J. Tuberc., in press.","DOI":"10.1016\/j.ijtb.2023.12.007"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e22","DOI":"10.35500\/jghs.2019.1.e22","article-title":"Cost and affordability analysis of TB LAMP and Xpert MTB\/RIF assays as routine diagnostic tests in peripheral laboratories in Malawi and Vietnam","volume":"1","author":"Sohn","year":"2019","journal-title":"J. Glob. Health Sci."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1128\/JCM.02157-10","article-title":"Comparison of the Xpert MTB\/RIF test with an IS6110-TaqMan real-time PCR assay for direct detection of Mycobacterium tuberculosis in respiratory and nonrespiratory specimens","volume":"49","author":"Armand","year":"2011","journal-title":"J. Clin. Microbiol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciaa241","article-title":"Treatment of nontuberculous mycobacterial pulmonary disease: An official ATS\/ERS\/ESCMID\/IDSA clinical practice guideline","volume":"71","author":"Daley","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1164\/rccm.201311-1974OC","article-title":"Impact of GeneXpert MTB\/RIF on patients and tuberculosis programs in a low-burden setting. a hypothetical trial","volume":"189","author":"Davis","year":"2014","journal-title":"Am J Respir Crit Care Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1086\/591974","article-title":"Tuberculosis transmission by patients with smear-negative pulmonary tuberculosis in a large cohort in the Netherlands","volume":"47","author":"Tostmann","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.jinf.2019.12.023","article-title":"Infectiousness of patients with smear-negative pulmonary tuberculosis, assessed by Real-time Polymerase Chain Reaction, Xpert\u24c7 MTB\/RIF","volume":"80","author":"Gomila","year":"2020","journal-title":"J. Infect."}],"container-title":["Biomedicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9059\/13\/10\/2416\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T15:34:59Z","timestamp":1759419299000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9059\/13\/10\/2416"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,2]]},"references-count":26,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["biomedicines13102416"],"URL":"https:\/\/doi.org\/10.3390\/biomedicines13102416","relation":{},"ISSN":["2227-9059"],"issn-type":[{"value":"2227-9059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,2]]}}}